* Equillium Inc EQ.OQ EQ.O is expected to show no change
in
quarterly revenue when it reports results on November 8
(estimated).
*
* Refinitiv's mean analyst estimate for Equillium Inc is
for a
loss of 38 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Equillium
Inc is
$12, above its last closing price of $1.71.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.41 -0.41 -0.41 Met 1.2
Mar. 31 2022 -0.37 -0.37 -0.45 Missed -20.8
Dec. 31 2021 -0.37 -0.34 -0.36 Missed -5.3
Sep. 30 2021 -0.34 -0.34 -0.35 Missed -3.4
Jun. -0.30 -0.31 -0.31 Met -1.1
30 2021
Mar. 31 2021 -0.33 -0.32 -0.33 Missed -2.5
Dec. 31 2020 -0.37 -0.40 -0.36 Beat 10.4
Sep. 30 2020 -0.42 -0.40 -0.31 Beat 22
This summary was machine generated November 4 at 12:46 GMT. All
figures in US dollars unless otherwise stated